CATALYST PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $589.0M | $491.7M | $398.2M | $214.2M | $140.8M |
| Operating income | $257.8M | $195.1M | $86.8M | $101.8M | $52.4M |
| Operating expenses | $206.5M | $190.4M | $226.9M | $76.9M | — |
| Cost of revenue | $87.3M | $68.8M | $52.0M | $34.4M | $21.9M |
| Cash from operations | $208.7M | $239.8M | $143.6M | $116.0M | $60.4M |
| Capital expenditure | $58,000 | $556,000 | $231,000 | $29,000 | $1.0M |
| Free cash flow | $208.6M | $239.3M | $143.4M | $116.0M | $59.4M |
| Share repurchases | $25.3M | $0 | $0 | $6.9M | $12.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.1B | $851.4M | $470.1M | $375.6M | $237.8M |
| Total liabilities | $149.7M | $123.8M | $82.2M | $75.2M | $31.0M |
Shares outstanding 122.4M · Free float 89.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.